Cogentech

What Cogentech does

Cogentech S.R.L. Società Benefit a Socio Unico is an Italian molecular diagnostics and translational research services company founded in 2018 and wholly owned by IFOM (Istituto Fondazione di Oncologia Molecolare ETS), which acts as sole shareholder and exercises direction and coordination over the entity. The company operates two UNI EN ISO 9001:2015 certified facilities — its registered office at Via Adamello 16, Milan (capital EUR 1.1M) and a Catania laboratory at the Sicily Science and Technology Park opened in 2019 — providing hereditary cancer diagnostics through its CGT Lab division and full-service research support across genomics, proteomics, metabolomics, histopathology, quantitative PCR, ddPCR, Sanger sequencing, single-cell omics (10X Genomics), single-molecule sequencing (Oxford Nanopore), and a mouse genetics facility authorized by the Italian Ministry of Health.

Cogentech's diagnostic portfolio centers on NGS-based hereditary cancer testing, anchored by proprietary panels including OncoPan® (37 genes for therapeutic targets and inherited cancer syndromes, including BRCA1/2 SNV/CNV and PRS), OncoHRD (PARP inhibitor eligibility via HRD scar analysis integrating OncoPan with Low-Pass WGS and the Sophia Genetics Ginger pipeline), and OncoPed (predisposition genes for pediatric and rare adult cancers such as Li-Fraumeni, Cowden, Gorlin, DICER1, Carney syndromes). The company's flagship R&D output is the BiLiGeCT "holistic" liquid biopsy protocol, developed with MUR PON/FSC funding and concluding in 2022, which performs four NGS analyses on cfDNA from a single blood sample and integrates results via AI/algorithmic models to detect tumor signals in apparently healthy BRCA mutation carriers. Other R&D programs include diaRNAgnosis (H2020-MSCA-RISE) and STRIKE (Horizon Europe MSCA-DN), and the company uses CRISPR-Cas9 to build isogenic cell models for functional characterization of BRCA1/2 Variants of Unknown Significance.

Revenue is generated primarily through quote-based professional-services contracts with Italian hospitals, cancer centers, and academic research institutions (Fondazione IRCCS INT Milan, IRE-IFO Rome, IOM Catania, IRST Meldola, IEO Milan, University of Turin, University of Trento, etc.), complemented by R&D grant income from the Italian MUR, the European Commission, and participation as an operational NGS partner in multi-center clinical trials including IFOM-sponsored ARETHUSA and Horizon Europe SAGITTARIUS. Go-to-market is sales-led and event-driven, leveraging scientific publications in journals such as Nature Communications and Science Advances, conference participation (Expolab 2022, AIFET national meeting), and institutional referral networks; the company invests more than 20% of spending in R&D and has not disclosed pricing publicly. In May 2023, TTFactor merged into Cogentech.

Name

Cogentech

Legal name

Cogentech S.R.L. Società Benefit a Socio Unico

Website

https://cogentech.it

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Cogentech is an Italian ISO 9001-certified molecular diagnostics and translational research services company, wholly owned by IFOM, providing hereditary cancer genetic testing (OncoPan®, OncoHRD, OncoPed) and full-service laboratory support across genomics, proteomics, metabolomics, and histopathology to Italian hospitals, academic researchers, and clinical-trial sponsors.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics and Translational Genomics Laboratory Services

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB)

Keywords

• Hereditary cancer diagnostics
• Next generation sequencing services
• Proteomics metabolomics services
• Liquid biopsy diagnostics
• Translational genomics laboratory

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Diagnostic Genetic Testing Services (CGT Lab): The CGT (Cancer Genetics Testing) Lab provides genetic testing services for hereditary cancer diagnostics. Revenue is generated through clinical testing services billed to hospitals, healthcare systems, and patients. Services include BRCA1/2 testing, multi-gene NGS panels (OncoPan, OncoPed), and cancer risk assessment tests. The diagnostic services are provided to clinical clients and are subject to ISO 9001 certification.
2. Scientific Research Services: Full-service laboratory contracts providing DNA Sanger Sequencing, Next Generation Sequencing (NGS), Genomic Unit, Histopathology, Integrated Genomics, Biological Research Facility (Mouse Genetics), Proteomics & Metabolomics, and Quantitative PCR services to external research clients, pharmaceutical companies, and clinical trial networks. Revenue is generated through per-project service contracts, service fees, and reagent/flowcell supplies.
3. R&D Project Grants and Collaborations: Cogentech receives government and institutional funding for research projects including the BiLiGeCT project (PON/FSC 2014-2020, grant from MUR), diaRNAgnosis (H2020-MSCA-RISE), and STRIKE (HORIZON-MSCA-2021-DN). Cogentech acts as lead partner and receives grant funding for development of diagnostic technologies.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Cogentech is an Italian molecular diagnostics and translational research services laboratory that provides hereditary cancer genetic testing (through its CGT Lab diagnostic branch) and a broad portfolio of full-service research laboratory contracts, including DNA Sanger sequencing, next-generation sequencing (NGS, single-cell, Nanopore), quantitative/digital PCR, proteomics and metabolomics (LC-MS/MS), histopathology, mouse genetics, and bioinformatics with AI tools. The company sells its services primarily to hospitals, cancer centers, clinical geneticists, academic and biomedical research institutions, pharmaceutical companies, and multi-center clinical trial networks, with revenue from per-project service contracts, ISO 9001-certified diagnostic testing, and government/EU grant-funded R&D collaborations.

Product overview

Cogentech is a Benefit Corporation affiliated with IFOM (Istituto Fondazione di Oncologia Molecolare) offering a comprehensive portfolio of genetic testing, diagnostic, and research services for hereditary cancer management. The core offering includes the CGT Lab diagnostic branch providing hereditary cancer testing, with key products including OncoPan® (37-gene NGS panel for pancreatic cancer), OncoHRD (BRCA/HRD analysis for PARP inhibitors), and OncoPed (pediatric cancer NGS panel). Scientific services include Genomic Unit (NGS, single-cell 10X Genomics, Oxford Nanopore), Integrated Genomics Unit (molecular biology, histopathology, bioinformatics), DNA Sanger Sequencing, Quantitative PCR, Proteomics & Metabolomics (mass spectrometry), Histopathology, and Biological Research Facility. R&D projects include BiLiGeCT (liquid biopsy protocol) and diaRNAgnosis (circulating RNA detection). The company operates ISO 9001:2015 certified laboratories in Milan and Catania, Italy.

Differentiator

Problem solved

Functional benefit

Brands

• OncoPan®: Strategic next-generation sequencing (NGS) panel of 37 genes for identification of therapeutic targets and inherited cancer syndromes, particularly for pancreatic ductal adenocarcinoma.
• OncoHRD
• OncoPed
• CGT Lab

Products and services

• CGT Lab - Hereditary Cancer Diagnostic Testing

Quantifiable outcome

• Over 1,000 molecular markers identified for prostate, lung, and colon cancer detection via exosome analysis
• +5 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature10 records

Partnerships

13 partnerships are on record, tiered minor and core.

• European Institute of Oncology (IEO), MilanminorStrategic or Co-development Partner · 1 January 2023IEO collaborated with Cogentech and Istituto Superiore di Sanità on the BI-ALCL project (2021-2022), commissioned by the Ministry of Health, to identify germline molecular alterations associated with breast implant-associated anaplastic large cell lymphoma (BI-ALCL) through whole exome sequencing.
• Università La Sapienza, RomeminorStrategic or Co-development Partner · 1 January 2023Università La Sapienza collaborated with Cogentech, Istituto Superiore di Sanità, and IEO on the BI-ALCL project commissioned by the Ministry of Health to study genetic factors in breast implant-associated lymphoma.
• DESTINA Genomica SL (Spain)minorStrategic or Co-development Partner · 1 January 2022DESTINA Genomica SL (Spain) is a partner in the diaRNAgnosis project (H2020-MSCA-RISE-2020 n. 101007934), collaborating with Cogentech to develop the ODG Platform for direct quantitative measurement of circulating RNA molecules for cancer biomarker detection.
• University of Trento (Italy)minorStrategic or Co-development Partner · 1 January 2022The University of Trento is a partner in the diaRNAgnosis project (H2020-MSCA-RISE), contributing academic research expertise to the cancer ccfRNA biomarker development consortium.
• University of Granada (Spain)minorStrategic or Co-development Partner · 1 January 2022The University of Granada is a partner in the diaRNAgnosis project (H2020-MSCA-RISE), contributing academic research expertise to the cancer ccfRNA biomarker development consortium.
• Princess Máxima Center (The Netherlands)minorStrategic or Co-development Partner · 1 January 2022Princess Máxima Center (The Netherlands) is a partner in the diaRNAgnosis project (H2020-MSCA-RISE), contributing academic research expertise to the cancer ccfRNA biomarker development consortium, focusing on testicular germ cell tumour biomarkers.
• Thomas Jefferson University, Philadelphia, USAminorStrategic or Co-development Partner · 1 January 2021Thomas Jefferson University (Philadelphia, USA) established a collaboration within the BiLiGeCT project for the development of liquid biopsy technologies and deep learning algorithms for patient-specific biomarker profiling.
• Università Cattolica del Sacro Cuore, RomeminorStrategic or Co-development Partner · 1 January 2021Università Cattolica del Sacro Cuore (Rome) entered into collaboration within the BiLiGeCT project for liquid biopsy research and biomarker development.
• IFOM - Istituto Fondazione di Oncologia Molecolare ETScoreStrategic or Co-development Partner · 1 July 2019IFOM is Cogentech's sole shareholder and primary scientific partner. Cogentech operates under IFOM's direction and coordination (attività di direzione e coordinamento). Cogentech and IFOM conduct joint cutting-edge research on genes, proteins, and molecular mechanisms involved in cancer development, with the goal of developing new drugs and cures. IFOM sponsors the ARETHUSA clinical trial in which Cogentech participates as an NGS sequencing service provider. Cogentech is co-located with IFOM at Via Adamello 16, Milan.
• CINMPIS (Consorzio Interuniversitario Nazionale Metodologie e Processi Innovativi di Sintesi)coreStrategic or Co-development Partner · 1 July 2019CINMPIS is a consortium involving the University of Catania and University of Messina. It is a core partner in the BiLiGeCT project (PON/FSC 2014-2020, project n. ARS01_00492), providing research collaboration for liquid biopsy development. Cogentech serves as lead partner with CINMPIS contributing academic research capabilities.
• Istituto Superiore di Sanità (ISS)coreStrategic or Co-development Partner · 1 July 2019The Italian National Institute of Health is a core partner in the BiLiGeCT project, responsible for molecular analysis of exosome samples and bioinformatics tool development for liquid biopsy applications. ISS researchers coordinated the exosome analysis work that identified over 1,000 molecular markers for prostate, lung, and colon cancer.
• Università degli Studi di Torino (UniTO)coreStrategic or Co-development Partner · 1 July 2019The University of Turin collaborated with Istituto Oncologico del Mediterraneo (IOM) in the BiLiGeCT project for identification of mutational signatures in colorectal cancer for clinical management. UniTO performed NGS sequencing and bioinformatics analysis on tumor DNA and cfDNA from colorectal cancer patients recruited by IOM.
• Istituto Oncologico del Mediterraneo (IOM), CataniacoreStrategic or Co-development Partner · 1 July 2019IOM is a core clinical partner in the BiLiGeCT project, responsible for recruiting colorectal cancer patients and collecting serial blood samples through venous blood draws. IOM also coordinated the project locally in Sicily, collaborating with Cogentech's Catania unit.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Centogene: German rare disease diagnostics company with European focus, offering genetic testing and clinical interpretation. Comparable as a European-based specialty diagnostics lab with similar hereditary disease focus.
• Macrogen: South Korea-based genomic services company offering NGS, Sanger sequencing, and bioinformatics to academic and clinical clients. Comparable to Cogentech as a full-service genomics CRO serving research institutions internationally.
• SOPHiA Genetics: Switzerland-based genomic analysis platform whose Ginger bioinformatics pipeline is integrated into Cogentech's OncoHRD product. Comparable as a genomics informatics and clinical genomics company serving cancer diagnostics customers.

Broad incumbents

• Ambry Genetics: US-based clinical genetics laboratory specializing in hereditary cancer testing (BRCA, multi-gene panels). Direct competitor in hereditary cancer diagnostics with comparable NGS panel approach.
• NeoGenomics: US oncology-focused clinical laboratory offering NGS, IHC, and molecular testing for cancer patients. Comparable to Cogentech's pathology and molecular diagnostics services for clinical oncology use cases.
• Eurofins Genomics: Global genomic services provider offering Sanger sequencing, NGS, oligonucleotide synthesis, and related services. Directly comparable to Cogentech's scientific services division operating at much larger scale across Europe.
• Myriad Genetics: Leading US hereditary cancer testing company (BRACAnalysis, myRisk) with established commercial infrastructure. Comparable to Cogentech's CGT Lab hereditary cancer diagnostics franchise, though at vastly larger scale and with proprietary IP.
• Synlab Italia: Italian arm of European clinical diagnostics network providing medical laboratory services including genetic testing. Comparable as a clinical laboratory serving Italian healthcare providers.

Regional players

• Personal Genomics: Italian genetic testing company offering hereditary cancer and pharmacogenomic testing. Direct Italian market competitor to Cogentech's CGT Lab hereditary cancer diagnostics.
• AB Analitica: Italian clinical diagnostics company specializing in molecular biology and genetic testing. Comparable as a regional Italian player in molecular diagnostics and laboratory services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cogentechsrl

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cogentech